The value of convalescent plasma therapy as a strategy to decrease hospitalization in COVID-19 patients: A randomized clinical trial.

Theresia Monica RAHARDJO; Hendra SUBROTO; Christian ADIUTAMA; Aloysius SURYAWAN

Return

The value of convalescent plasma therapy as a strategy to decrease hospitalization in COVID-19 patients: A randomized clinical trial.

Author: Theresia Monica RAHARDJO ¹ ; Hendra SUBROTO ² ; Christian ADIUTAMA ³ ; Aloysius SURYAWAN ¹
Author Information

1. Faculty of Medicine, Maranatha Christian University, Bandung, Indonesia
2. Department of Clinical Pathology, Faculty of Medicine, Maranatha Christian University, Bandung, Indonesia
3. Medical Faculty Universitas Pendidikan Indonesia, Bandung, Indonesia
Publication Type:Journal Article, Original
MeSH: Pandemics; Polymerase Chain Reaction; Randomized Controlled Trial; Emergency Service, Hospital; Hospitalization; Emergencies; Covid-19; Length Of Stay; Antibodies
From: Acta Medica Philippina 2026;60(8):51-58
CountryPhilippines
Abstract: BACKGROUND
Convalescent plasma therapy (CPT) has been utilized as an emergency and last-resort treatment for viral infections, particularly in the absence of vaccine. During the COVID-19 pandemic, CPT was implemented worldwide based on its potential to provide passive immunity through SARS-CoV-2 antibodies. While numerous studies explored the effectiveness of CPT to cure COVID-19 patients, there has no research specifically focused on superiority of CPT impact on the length of hospitalization.
OBJECTIVE
This study aimed to evaluate the effect of CPT on the length of hospital stay among patients with moderate COVID-19.
METHODS
This is a single blind randomized controlled trial (RCT) study involved 30 moderate-grade COVID-19 patients age 18-75 years with positive PCR result treated at Unggul Karsa Medika Hospital Bandung from February 2 to May 31, 2022. Moderate-grade COVID-19 defined by clinical pneumonia symptoms based on World Health Organization (WHO) criteria. Eligible patients were randomly assigned (1:1 ratio) and outcome assessors were blinded, while care providers and patients were not due to the intervention nature. The intervention arm (n=15) received 200 ml of high-titer CPT within 24 hours of admission with standard care and the control arm (n=15) received standard care only. The primary outcome measured was the length of stay (LOS) in both the Emergency Room (ER) and COVID-19 High Care Unit (HCU). Data were analyzed using independent T-tests.
RESULTS
Thirty (30) eligible patients (mean age 40 years; 53% female) were analyzed for the primary outcome and all completed follow-ups. The CPT group had significantly shorter LOS than controls (mean difference for ER:-32.7 hours [95% CI:-45.0,-20.4]; HCU:-33.3 hours [95% CI:- 45.8,-20.8]; p
CONCLUSION
The administration of CPT may reduce the LOS in moderate COVID-19 patients. However, the small sample size can limit the generalizability of this result and larger sample studies are needed to strengthen this finding. Early CPT implementation may improve patient management and optimize healthcare resource utilization during the pandemic.